Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes

European Journal of Clinical Pharmacology

Volumn 68, Issue 5, 2012, Pages 579-588

  Hayato, Seiichi ^b   Hasegawa, Setsuo ^c   Hojo, Seiichiro ^b   Okawa, Hiroki ^b   Abe, Hiroaki ^b   Sugisaki, Nobuyuki ^b   Munesue, Masahiro ^b   Horai, Yukio ^a,b   Ohnishi, Akihiro ^a,d  

^a Clinical Science Scientific and Operational Clinical Support Core Function Unit   (Japan)

^b EISAI CO LTD   (Japan)

^c Sekino Clinical Pharmacology Clinic   (Japan)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CYP2C19 genotype; GERD; Nocturnal gastric pH; Pharmacodynamics; Pharmacokinetics; Rabeprazole

Indexed keywords

CYTOCHROME P450 2C19; RABEPRAZOLE;

ADULT; ANTISECRETORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYP2C19 GENOTYPE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; JAPANESE; MALE; NORMAL HUMAN; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID SECRETION; STOMACH PH; TIME TO MAXIMUM PLASMA CONCENTRATION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; GASTRIC ACID; GASTRIC MUCOSA; GENOTYPE; H(+)-K(+)-EXCHANGING ATPASE; HALF-LIFE; HUMANS; JAPAN; MALE; MODELS, BIOLOGICAL; POLYMORPHISM, GENETIC; PROTON PUMP INHIBITORS; YOUNG ADULT;

EID: 84864280972     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1164-7     Document Type: Article

References (30)

1. Sachs G (1997) Proton pump inhibitors and acid-related diseases. Pharmacotherapy 17:22-37 (Pubitemid 27057116)
2. Fass R, Shapiro M, Dekel R, Sewell J (2005) Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next? Aliment Pharmacol Ther 22:79-94 (Pubitemid 41039696)
3. Peghini PL, Katz PO, Bracy NA, Castell DO (1998) Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 93:763-767 (Pubitemid 29063918)
4. Hatlebakk JG, Katz PO, Kuo B, Castell DO (1998) Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 12:1235-1240 (Pubitemid 28565964)
5. Peghini PL, Katz PO, Castell DO (1998) Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 115:1335-1339 (Pubitemid 28545982)
6. Adachi K, Fujishiro H, Katsube T, Yuki M, Ono M, Kawamura A, Rumi MA, Watanabe M, Kinoshita Y (2001) Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol 16:1191-1196 (Pubitemid 34088263)
7. Pace F, Pallotta S, Casalini S, Porro GB (2007) A review of rabeprazole in the treatment of acid-related diseases. Ther Clin Risk Manag 3:363-379 (Pubitemid 47214980)
8. Lew EA, Barbuti RC, Kovacs TO, Sytnic B, Humphries TJ, Walsh JH (1998) An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810). Aliment Pharmacol Ther 12:667-672 (Pubitemid 28327964)
9. Williams MP, Blanshard C, Millson C, Sercombe J, Pounder RE (2000) A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects. Aliment Pharmacol Ther 14:691-699 (Pubitemid 30352734)
10. Ohning GV, Barbuti RC, Kovacs TO, Sytnik B, Humphries TJ, Walsh JH (2000) Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection. Aliment Pharmacol Ther 14:701-708 (Pubitemid 30352735)
11. Robinson M, Maton PN, Rodriguez S, Greenwood B, Humphries TJ (1997) Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 11:973-980
12. Shimatani T, Inoue M, Kuroiwa T, Horikawa Y (2004) Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression. Aliment Pharmacol Ther 19:113-122 (Pubitemid 38125644)
13. Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M, Ohashi K, Ishizaki T (2004) Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2 C19 genotype status. Clin Pharmacol Ther 76:290-301 (Pubitemid 39313119)
14. Kinoshita Y, Ashida K, Hongo M; Japan Rabeprazole Study Group for NERD (2011) Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. Aliment Pharmacol Ther 33:213-224
15. Andersson T (1996) Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 31:9-28 (Pubitemid 26238200)
16. Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, Xiao F, Kosuge K, Nakagawa K, Hanai H, Chiba K, Ohashi K, Ishizaki T (2001) Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 15:1929-1937 (Pubitemid 34014349)
17. Shi S, Klotz U (2008) Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 64:935-951
18. Ishizaki T, Horai Y (1999) Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment Pharmacol Ther 13(Suppl 3):27-36 (Pubitemid 29389409)
19. Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, Kobayashi K, Chiba K, Ishizaki T (1995) Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4hydroxylation status. Clin Pharmacol Ther 58:143-154
20. Adachi K, Katsube T, Kawamura A, Takashima T, Yuki M, Amano K, Ishihara S, Fukuda R, Watanabe M, Kinoshita Y (2000) CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 14:1259-1266
21. Horai Y, Kimura M, Furuie H, Matsuguma K, Irie S, Koga Y, Nagahama T, Murakami M, Matsui T, Yao T, Urae A, Ishizaki T (2001) Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol Ther 15:793-803 (Pubitemid 32500425)
22. Ieiri I, Kishimoto Y, Okochi H, Momiyama K, Morita T, Kitano M et al (2001) Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. Eur J Clin Pharmacol 57:485-492
23. Bell NJ, Hunt RH (1992) Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 33:118-124
24. Katz PO, Johnson DA, Levine D, Rohss K, Junghard O, Astrand M, Nagy P (2010) A model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing? Aliment Pharmacol Ther 32:443-447
25. Klotz U (2006) Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 44:297-302 (Pubitemid 44043771)
26. Andersson T, Rohss K, Bredberg E, Hassan-Alin M (2001) Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 15:1563-1569 (Pubitemid 32912398)
27. Junghard O, Hassan-Alin M, Hasselgren G (2002) The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH. Eur J Clin Pharmacol 58:453-458 (Pubitemid 35244918)
28. Gillen D, Wirz AA, Neithercut WD, Ardill JE, McColl KEL (1999) Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut 44:468-475 (Pubitemid 29169945)
29. Verdu EF, Armstrong D, Fraser R, Viani F, Idstrom JP, Cederberg C, Blum AL (1995) Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 36:539-543
30. Verdu EF, Armstrong D, Idstrom JP, Labenz J, Stolte M, Dorta G, Börsch G, Blum AL (1995) Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 37:743-748